芪苈强心胶囊辅助治疗扩张型心肌病继发慢性心力衰竭临床观察

Clinical observation on qiliqiangxin capsules in adjuvant treatment ofchronic heart failure secondary to dilated cardiomyopathy

目的 探究芪苈强心胶囊治疗扩张型心肌病(DCM)继发慢性心力衰竭(CHF)的临床效果。方法 选取本院2020年9月5日—2021年12月5日收治的103例DCM继发CHF患者作为研究对象,采用随机数字表法分成2组,对照组52例,脱落2例,完成观察病例50例,给予常规治疗;观察组51例,脱落1例,完成观察病例50例,给予加用芪苈强心胶囊,对比2组疗效,心功能、心室重塑指标及神经内分泌因子水平。结果 观察组治疗后总有效率为88.00%(44/50),高于对照组的70.00%(35/50),差异有统计学意义(χ^(2)=4.883,P=0.027);观察组治疗后LVESD、LVEDD分别为(57.36±7.13)mm、(46.82±7.03)mm,分别低于对照组的(63.50±7.34)mm、(52.34±6.87)mm,差异有统计学意义(t=4.243,P<0.001;t=3.971,P<0.001);观察组治疗后LVEF为(52.47±4.83)%,高于对照组的(42.21±4.68)%,差异有统计学意义(t=10.787,P<0.001)。观察组治疗后IVSS、LVPWT、PWD、PWS分别为(10.01±1.41) mm、(9.43±1.01)mm、(11.45±1.32)mm、(10.75±1.62)mm,分别低于对照组的(10.86±1.53)mm、(10.24±1.42)mm、(12.31±1.53)mm、(11.62±1.82)mm,差异有统计学意义(P均<0.05)。观察组治疗后AngⅡ、ALD、NE、NTpro-cNP分别为(80.47±29.31)ng/L、(80.57±24.16)pmol/L、(410.81±42.25)ng/L、(2762.58±390.27)ng/L,分别低于对照组的(94.21±33.08)ng/L、(96.63±25.21)pmol/L、(450.27±51.42) ng/L、(3250.53±540.71)ng/L,差异有统计学意义(P均<0.05)。结论 在常规治疗基础上辅以芪苈强心胶囊治疗DCM继发CHF患者疗效确切,能够提高患者心功能、改善心室重塑及神经内分泌因子水平,值得临床推广使用。

Objective To explore the clinical effect of qiliqiangxin capsules on chronic heart failure(CHF)second⁃ary to dilated cardiomyopathy(DCM).Methods A total of 100 cases of DCM secondary CHF admitted to our hospital from September 5,2020,to December 5,2021,were divided into two groups by lottery,50 cases of conventional treatment in the control group and 50 cases of observation group plus qiliqiangxin capsule,and the efficacy,cardiac function,ventricular remodeling indexes,and neuroendocrine factor levels were compared between the two groups.Results The total effective rate of the observation group was 88.00%(44/50),which was higher than that of the control group(70.00%)(35/50)(χ^(2)=4.883,P=0.027).LVESD and LVEDD in the observation group were(57.36±7.13)mm and(46.82±7.03)mm,respectively,lower than those in the control group(63.50±7.34)mm and(52.34±6.87)mm(t=4.243,P<0.001;t=3.971,P<0.001).The LVEF of the observation group was(52.47±4.83)%,higher than that of the control group(42.21±4.68)%(t=10.787,P<0.001).IVSS,LVPWT,PWD,and PWS in the observation group after treatment were(10.01±1.41、9.43±1.01、11.45±1.32、10.75±1.62)mm,respectively,which were lower than those in the control group:(10.86±1.53、10.24±1.42、12.31±1.53、11.62±1.82)mm,and the differences were statistically significant(all P<0.05).After treatment,AngⅡ,ALD,NE,and NTpro⁃cNP in the observation group were(80.47±29.31)ng/L,(80.57±24.16)pmol/L,(410.81±42.25)ng/L,(2762.58±390.27)ng/L,respectively,which were lower than those of the control group:(94.21±33.08)ng/L,(96.63±25.21)pmol/L,(450.27±51.42)ng/L,and(3250.53±540.71)ng/L respectively,and the differences were statistically significant(all P<0.05).Conclusion On the basis of conventional treatment,supplemented with qiliqiangxin capsules in the treatment of patients with CHF secondary DCM has a definite curative effect,which can improve cardiac function,ventricular remodeling,and neuroendocrine factor levels,and is worthy of clinical pro⁃motion.